AMENDMENTS

Listing of Claims:

The following listing of claims replaces all previous listings or versions thereof:

- 1.-38 (cancelled)
- 39. (currently amended) A method of identifying a modulator of a Fortilin polypeptide comprising:
 - (a) contacting an isolated Fortilin polypeptide comprising the amino acid sequence of SEO ID NO:2 with a candidate substance; and
 - (b) assaying whether the candidate substance enhances or inhibits the Fortilin polypeptide <u>binding</u> activity, wherein a candidate substance that enhances or inhibits Fortilin polypeptide activity is a modulator of the Fortilin polypeptide.
- 40. (previously presented) The method of claim 39, wherein the assaying compares the activity of the Fortilin polypeptide in the presence and absence of the candidate substance.
- 41. 45. (cancelled)
- 46. (previously presented) The method of claim 39, wherein the assaying is done by determining whether a p53-Fortilin interaction is disrupted.
- 47. (previously presented) The method of claim 39, wherein the assaying is done by determining whether a MCL1-Fortilin interaction is disrupted.
- 48.-62. (cancelled)
- 63. (previously presented) The method of claim 39, wherein the candidate substance is a polypeptide.
- 64. (previously presented) The method of claim 63, wherein the polypeptide is an antibody.

- 65. (cancelled)
- 66. (previously presented) The method of claim 39, wherein the candidate substance is a small molecule.
- 67. (cancelled)
- 68. (currently amended) A method of identifying a modulator of a Fortilin polypeptide comprising:
 - (a) contacting a candidate modulator with isolated, recombinant cells expressing a Fortilin polypeptide comprising the amino acid sequence of SEQ ID NO:2;
 - (b) measuring the level of Fortilin activity or expression of the cell; and,
 - comparing the level of Fortilin activity or expression of the cells to the level of Fortilin activity or expression—of cells not expressing a Fortilin polypeptide comprising the amino acid sequence of SEQ ID NO:2 not contacted with the candidate—modulator, wherein Fortilin activity is cell cycle progression or inhibition of apoptosis,

wherein a difference between the level of Fortilin activity or expression indicates that the candidate modulator is a modulator of a Fortilin polypeptide.

69.-78. (cancelled)

- 79. (previously presented) The method of claim 68, wherein the candidate substance is a polypeptide.
- 80. (previously presented) The method of claim 79, wherein the polypeptide is an antibody.
- 81. (previously presented) The method of claim 68, wherein the candidate substance is a nucleic acid.

- 82. (previously presented) The method of claim 81, wherein the nucleic acid comprises at least 20 contiguous nucleotides identical or complementary to SEQ ID NO:1.
- 83. (previously presented) The method of claim 68, wherein the candidate substance is a small molecule.

84.-87. (cancelled)

88. (previously presented) The method of claim 68, wherein the candidate modulator acts directly on a Fortilin gene or Fortilin RNA.

89.-92. (cancelled)

- 93. (New) A method of identifying a modulator of a Fortilin polypeptide comprising:
 - (a) contacting a candidate modulator with isolated, recombinant cells expressing a Fortilin polypeptide comprising the amino acid sequence of SEQ ID NO:2;
 - (b) measuring the level of Fortilin expression of the cell; and,
 - (c) comparing the level of Fortilin expression of the cells to the level of Fortilin expression of cells not contacted with the candidate modulator,

wherein a difference between the level of Fortilin expression indicates that the candidate modulator is a modulator of a Fortilin polypeptide.

- 94. (New) The method of claim 93, wherein the level of Fortilin polypeptide is measured.
- 95. (New) The method of claim 93, wherein the level of Fortilin mRNA is measured.
- 96. (New) The method of claim 93, wherein Fortilin half-life is measured.
- 97. (New) The method of claim 93, wherein the candidate substance is a polypeptide.
- 98. (New) The method of claim 97, wherein the polypeptide is an antibody.

- 99. (New) The method of claim 93, wherein the candidate substance is a nucleic acid.
- 100. (New) The method of claim 99, wherein the nucleic acid comprises at least 20 contiguous nucleotides identical or complementary to SEQ ID NO:1.
- 101. (New) The method of claim 93, wherein the candidate substance is a small molecule.